Sirosis Hepatis

01Pathophysiology

Cirrhosis represents the final common pathway of virtually all forms of chronic liver injury. Regardless of etiology, the fundamental sequence involves repeated cycles of hepatocyte necrosis followed by fibrosis and nodular regeneration, ultimately replacing the normal lobular architecture with structurally abnormal tissue.

The central cellular player is the hepatic stellate cell (Ito cell). In a healthy liver, stellate cells remain quiescent and serve primarily as storage sites for vitamin A. When chronic injury occurs, inflammatory cytokines (particularly TGF-beta) activate these cells, transforming them into myofibroblasts that deposit excessive extracellular matrix, predominantly collagen types I and III, within the space of Disse. This collagen deposition obliterates the normal fenestrations of the sinusoidal endothelium, a process called capillarization of the sinusoids. The result is increased intrahepatic vascular resistance, which is the primary driver of portal hypertension.

Portal hypertension is defined as a hepatic venous pressure gradient (HVPG) exceeding 5 mmHg. It becomes clinically significant at greater than or equal to 10 mmHg, at which point complications such as varices and ascites begin to develop. The elevated portal pressure forces blood to seek alternative routes back to the systemic circulation through portosystemic collaterals. These collaterals explain the classic clinical findings: esophageal and gastric varices (left gastric vein pathway), caput medusae (paraumbilical veins), and hemorrhoids (inferior mesenteric to rectal vein pathway). Collateral flow through the splenic vein also results in congestive splenomegaly, which in turn causes hypersplenism and the thrombocytopenia that is often the very first laboratory clue to underlying cirrhosis.

Ascites develops through a cascade that begins with portal hypertension causing splanchnic arteriolar vasodilation (mediated by nitric oxide). This vasodilation reduces the effective arterial blood volume, triggering compensatory activation of the renin-angiotensin-aldosterone system (RAAS), the sympathetic nervous system, and nonosmotic release of ADH. The net effect is avid renal sodium and water retention. Simultaneously, hypoalbuminemia from decreased hepatic synthetic function lowers plasma oncotic pressure. The combination of high hydrostatic pressure in the portal system and low oncotic pressure drives fluid into the peritoneal cavity.

Hepatic encephalopathy occurs because portosystemic shunting allows ammonia and other gut-derived neurotoxins to bypass hepatic detoxification and enter the systemic circulation. Ammonia crosses the blood-brain barrier and is metabolized by astrocytes through the enzyme glutamine synthetase, producing glutamine. Glutamine accumulation within astrocytes creates osmotic stress, leading to astrocyte swelling and cerebral edema at the cellular level, producing the clinical spectrum from subtle cognitive changes to frank coma.

The coagulopathy of cirrhosis reflects impaired hepatic synthesis of clotting factors (all factors except von Willebrand factor and factor VIII, which are produced by endothelial cells). Prolonged prothrombin time and elevated INR are the laboratory correlates. This is compounded by thrombocytopenia from splenic sequestration.

Spider angiomata, palmar erythema, gynecomastia, and testicular atrophy all result from hyperestrogenism due to the failing liver's inability to metabolize and clear circulating estrogens. The distribution of spider angiomata in the territory of the superior vena cava (face, neck, upper chest, arms) is a frequently tested detail.

Hepatorenal syndrome represents the extreme of the hemodynamic derangement: severe splanchnic vasodilation triggers intense renal vasoconstriction, causing functional renal failure despite structurally normal kidneys. Hepatopulmonary syndrome involves intrapulmonary vascular dilation with right-to-left shunting, classically producing platypnea (dyspnea worsening when upright) and orthodeoxia (oxygen desaturation when upright).

02Classification and Clinical Manifestation

Compensated vs. Decompensated Cirrhosis

Child-Turcotte-Pugh (CTP) Score

Each parameter is scored 1, 2, or 3 points. Total score determines the class.

The mnemonic for CTP parameters is "ABCDE": Albumin, Bilirubin, Clotting (INR), Distension (ascites), Encephalopathy.

MELD Score

The Model for End-Stage Liver Disease score is calculated using three laboratory values:

$$MELD=3.78\times \ln (\text{bilirubin})+11.2\times \ln (\text{INR})+9.57\times \ln (\text{creatinine})+6.43MELD\; =\; 3.78\; \backslash times\; \backslash ln(\backslash text\{bilirubin\})\; +\; 11.2\; \backslash times\; \backslash ln(\backslash text\{INR\})\; +\; 9.57\; \backslash times\; \backslash ln(\backslash text\{creatinine\})\; +\; 6.43$$

The MELD score is used primarily for organ allocation priority in liver transplantation. A score of 15 or above generally warrants transplant listing referral. The updated MELD-Na incorporates serum sodium, improving prognostic accuracy.

Hepatic Encephalopathy Grading (West Haven Criteria)

03Diagnostic Workup

The best initial test when cirrhosis is suspected is a combination of laboratory studies (CBC, CMP, coagulation panel) plus abdominal ultrasound with Doppler. The ultrasound is widely available, noninvasive, and can reveal the classic findings of a nodular liver contour, ascites, splenomegaly, and portal vein abnormalities. Doppler interrogation is important to assess for portal vein thrombosis and to detect reversal of portal flow (hepatofugal flow), which is pathognomonic for advanced portal hypertension.

Transient elastography (FibroScan) has become an increasingly central tool in clinical practice for staging fibrosis noninvasively. It measures liver stiffness using ultrasound-based shear wave velocity. A stiffness value above approximately 12.5 kPa is highly suggestive of cirrhosis. This test is particularly useful for monitoring disease progression and for avoiding biopsy in patients with clear clinical cirrhosis.

The most accurate (gold standard) test remains liver biopsy, which demonstrates the hallmark histological pattern of regenerative nodules completely encircled by fibrous septa. In practice, biopsy is reserved for cases where the diagnosis is uncertain, when the etiology is unclear despite noninvasive workup, or when concurrent pathology (such as autoimmune overlap or concurrent steatohepatitis) needs to be confirmed.

Every patient with newly diagnosed cirrhosis must undergo an etiologic workup to identify the underlying cause, because many etiologies have treatments that can halt or even partially reverse fibrosis. Simultaneously, screening EGD should be performed to assess for esophageal and gastric varices. Patients without varices on initial endoscopy should be rescreened every 2 to 3 years (or every 1 to 2 years if decompensated).

Hepatocellular carcinoma (HCC) surveillance with ultrasound and AFP every 6 months is mandatory for all patients with cirrhosis, regardless of etiology. This is one of the most commonly tested surveillance intervals on licensing exams.

A critical test to know in the setting of new-onset ascites or any hospitalized patient with ascites is diagnostic paracentesis. This should be performed immediately and should not be delayed. The ascitic fluid is analyzed for cell count with differential, albumin, total protein, and culture. The serum-ascites albumin gradient (SAAG) is calculated:

$$SAAG=\text{Serum albumin}-\text{Ascitic fluid albumin}SAAG\; =\; \backslash text\{Serum\; albumin\}\; -\; \backslash text\{Ascitic\; fluid\; albumin\}$$

A SAAG greater than or equal to 1.1 g/dL indicates portal hypertension as the cause of ascites (high sensitivity). A SAAG less than 1.1 suggests non-portal hypertensive causes such as peritoneal carcinomatosis or tuberculosis.

Spontaneous bacterial peritonitis (SBP) is diagnosed when the ascitic fluid polymorphonuclear (PMN) cell count exceeds 250 cells/mm3. Treatment should begin immediately without waiting for culture results.

04Management and Treatment

Ascites Management in Detail

The cornerstone of ascites management is sodium restriction to less than 2 g per day combined with dual diuretic therapy. The standard regimen is spironolactone 100 mg/day plus furosemide 40 mg/day, maintaining the classic 100:40 ratio. Doses can be titrated upward every 3 to 5 days (doubling both simultaneously to maintain the ratio) to a maximum of spironolactone 400 mg/day plus furosemide 160 mg/day. The rationale for spironolactone as the primary agent is that secondary hyperaldosteronism is the dominant sodium-retaining mechanism in cirrhotic ascites.

Monitor weight daily with a target loss of approximately 0.5 kg/day in patients without peripheral edema and 1 kg/day in those with peripheral edema. Monitor serum potassium, sodium, and renal function closely. Spironolactone can cause hyperkalemia and painful gynecomastia (if intolerable, substitute amiloride). Furosemide can cause hypokalemia and prerenal azotemia.

Refractory ascites (failure to respond to maximum diuretics plus sodium restriction, or diuretic-related complications precluding adequate dosing) is managed with serial large-volume paracentesis (LVP). When more than 5 liters of ascitic fluid are removed in a single session, intravenous albumin must be administered at 6 to 8 grams per liter removed to prevent paracentesis-induced circulatory dysfunction. TIPS (transjugular intrahepatic portosystemic shunt) is considered for patients requiring frequent LVP, provided they do not have severe hepatic encephalopathy or a Child-Pugh score of C with a score above 11.

Hepatic Encephalopathy Management in Detail

The first step is always to identify and treat the precipitant: infection (including SBP), gastrointestinal bleeding, constipation, electrolyte abnormalities (especially hypokalemia and hyponatremia), excessive dietary protein, sedating medications (benzodiazepines, opioids), and dehydration.

Lactulose is the first-line agent. It is a nonabsorbable disaccharide that is metabolized by colonic bacteria into organic acids, which lower colonic pH. This acidified environment converts ammonia ($N{H}_{3}NH\_3$) to ammonium ($N{H}_4^{+}NH\_4^+$), which is charged and cannot be reabsorbed across the colonic mucosa, thereby trapping ammonia in the gut lumen for fecal excretion. The dose is titrated to achieve 2 to 3 soft bowel movements per day.

Rifaximin 550 mg PO twice daily is added for secondary prophylaxis in patients with recurrent hepatic encephalopathy. Rifaximin is a poorly absorbed oral antibiotic that reduces ammonia-producing gut flora. The combination of lactulose plus rifaximin is more effective than lactulose alone for preventing recurrence.

Variceal Bleeding Management in Detail

Primary prophylaxis: All patients with medium or large varices should receive a nonselective beta-blocker (propranolol starting at 20 mg BID, nadolol starting at 40 mg daily, or carvedilol 6.25 mg BID titrated up to 12.5 mg BID). The goal is to reduce the resting heart rate by 25% or to a rate of 55 to 60 beats per minute. Carvedilol has the additional benefit of reducing intrahepatic resistance through its alpha-blocking properties and is increasingly preferred.

Acute variceal hemorrhage is a medical emergency. Management involves simultaneous resuscitation and intervention: IV octreotide (50 mcg bolus followed by a continuous infusion of 50 mcg/hr for 3 to 5 days) to reduce splanchnic blood flow, emergent upper endoscopy with band ligation within 12 hours, and prophylactic antibiotics (ceftriaxone 1 g IV daily for 7 days) to prevent SBP and bacteremia, which significantly reduces mortality. Avoid excessive fluid resuscitation and keep the hemoglobin target around 7 to 8 g/dL to avoid rebound increases in portal pressure.

If endoscopic therapy fails to control bleeding, balloon tamponade (Sengstaken-Blakemore or Minnesota tube) serves as a temporary bridge, and emergent TIPS is considered.

Secondary prophylaxis requires the combination of endoscopic band ligation (repeat every 2 to 4 weeks until varices are obliterated) plus nonselective beta-blockers. Neither modality alone is sufficient.

Liver Transplantation

Transplantation is the definitive treatment for decompensated cirrhosis. Patients with a MELD score of 15 or above should be referred for transplant evaluation. Indications include refractory ascites, recurrent variceal bleeding despite therapy, recurrent or persistent hepatic encephalopathy, hepatorenal syndrome, and hepatopulmonary syndrome. Key contraindications include active alcohol or substance use (most programs require 6 months of documented abstinence), extrahepatic malignancy, uncontrolled sepsis, and advanced cardiopulmonary disease.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most commonly missed pearl regarding cirrhosis is the significance of isolated thrombocytopenia. When a vignette describes a patient with fatigue, mildly abnormal liver tests, and a low platelet count without an obvious hematologic explanation, the test-writer is pointing you toward occult cirrhosis with portal hypertension and hypersplenism. Students frequently chase hematologic diagnoses (ITP, TTP) and overlook the liver.

Another frequent trap involves paracentesis timing. The exam will present a patient with known cirrhotic ascites who is admitted for a new complaint (fever, abdominal pain, altered mental status, or even an unrelated issue). The correct next step is diagnostic paracentesis to rule out SBP, regardless of whether the patient appears clinically infected. The vignette may try to tempt you with empiric antibiotics or CT imaging as the next step, but paracentesis always comes first when there is ascites in a hospitalized cirrhotic patient.

Students also commonly confuse the SAAG with the total protein content of ascitic fluid. A SAAG of 1.1 or greater tells you portal hypertension is present but does not distinguish cirrhotic ascites from cardiac ascites. To make that distinction, you look at the ascitic fluid total protein: less than 2.5 g/dL favors cirrhosis, while greater than 2.5 g/dL favors cardiac causes. This is a classic two-step reasoning question.

Regarding hepatic encephalopathy, a common mistake is ordering a serum ammonia level to diagnose or monitor the condition. While ammonia is elevated in most cases, levels correlate poorly with the severity of encephalopathy, and the diagnosis is clinical. The exam punishes students who select "check ammonia level" as a next step when the clinical picture already establishes the diagnosis. Instead, the correct answer is typically to identify the precipitant and start lactulose.

For variceal bleeding, students often forget the antibiotic prophylaxis component. Ceftriaxone 1 g IV daily for 7 days during an acute variceal bleed is not just supportive care but a mortality-reducing intervention that must not be omitted.

Finally, be aware that beta-blockers may need to be discontinued in patients with cirrhosis who develop refractory ascites, SBP, or hepatorenal syndrome. In these hemodynamically fragile patients, beta-blockers can worsen systemic hypotension and reduce cardiac output, paradoxically increasing mortality. This concept, sometimes referenced as the "window theory" of beta-blocker use in cirrhosis, is a nuanced but increasingly tested point.

The core competency tested across cirrhosis questions is your ability to recognize the constellation of portal hypertensive complications, sequence diagnostic and therapeutic interventions correctly (paracentesis before antibiotics, identify precipitant before treating encephalopathy, band ligation plus drugs for secondary prophylaxis), and recall the thresholds that drive management decisions (SAAG of 1.1, PMN count of 250, MELD of 15, CTP classification).